Tonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain
30 Luglio 2024 - 2:00PM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a fully-integrated biopharmaceutical company with
marketed products and a pipeline of development candidates, today
announced a poster presentation at the International Association
for the Study of Pain (IASP) 2024 World Congress on Pain, being
held August 5-9, 2024 in Amsterdam, Netherlands. Details on the
presentation can be found below.
A copy of the Company’s poster presentations
will be available under the Scientific Presentations tab of the
Tonix website at www.tonixpharma.com following the conference.
Additional meeting information can be found on the IASP website
here.
Poster Presentation Details
Presenter: |
Seth Lederman, M.D., Chief Executive Officer of Tonix
Pharmaceuticals |
Title: |
Targeting Fibromyalgia Non-Restorative Sleep with Bedtime TNX-102
SL (Sublingual Cyclobenzaprine HCl): Results of the Positive Phase
3 RESILIENT Trial Consistent with Syndromic Improvement |
Abstract: |
#WE685 |
Date/Time: |
Wednesday, August 7, 2024, 3:15 p.m. CEST |
|
|
Tonix Pharmaceuticals Holding
Corp.**
Tonix is a fully-integrated biopharmaceutical
company focused on developing, licensing and commercializing
therapeutics to treat and prevent human disease and alleviate
suffering. Tonix’s development portfolio is focused on central
nervous system (CNS) disorders. Tonix’s priority is to submit a New
Drug Application (NDA) to the FDA in the second half of 2024 for
Tonmya*, a product candidate for which two statistically
significant Phase 3 studies have been completed for the management
of fibromyalgia. The FDA has granted Fast Track designation to
Tonmya for the management of fibromyalgia. TNX-102 SL is also being
developed to treat acute stress reaction. Tonix’s CNS portfolio
includes TNX-1300 (cocaine esterase), a biologic designed to treat
cocaine intoxication that has Breakthrough Therapy designation.
Tonix’s immunology development portfolio consists of biologics to
address organ transplant rejection, autoimmunity and cancer,
including TNX-1500, which is a humanized monoclonal antibody
targeting CD40-ligand (CD40L or CD154) being developed for the
prevention of allograft rejection and for the treatment of
autoimmune diseases. Tonix also has product candidates in
development in the areas of rare disease and infectious disease.
Tonix Medicines, our commercial subsidiary, markets Zembrace®
SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan
nasal spray) 10 mg for the treatment of acute migraine with or
without aura in adults.
*Tonmya™ is conditionally accepted by the U.S.
Food and Drug Administration as the tradename for TNX-102 SL for
the management of fibromyalgia. Tonmya has not been approved for
any indication.
**Tonix’s product development candidates are
investigational new drugs or biologics and have not been approved
for any indication.
Zembrace SymTouch and Tosymra are registered
trademarks of Tonix Medicines. All other marks are property of
their respective owners.
This press release and further information about
Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to, risks
related to the failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations; risks related to the failure to
successfully market any of our products; risks related to the
timing and progress of clinical development of our product
candidates; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial
competition. As with any pharmaceutical under development, there
are significant risks in the development, regulatory approval and
commercialization of new products. Tonix does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in the Annual
Report on Form 10-K for the year ended December 31, 2023, as filed
with the Securities and Exchange Commission (the “SEC”) on April 1,
2024, and periodic reports filed with the SEC on or after the date
thereof. All of Tonix's forward-looking statements are expressly
qualified by all such risk factors and other cautionary statements.
The information set forth herein speaks only as of the date
thereof.
Investor Contact
Jessica MorrisTonix
Pharmaceuticalsinvestor.relations@tonixpharma.com (862)
904-8182
Peter VozzoICR Westwickepeter.vozzo@westwicke.com (443)
213-0505
Media Contact
Katie
DodgeLaVoieHealthSciencekdodge@lavoiehealthscience.com(978)
360-3151
Grafico Azioni Tonix Pharmaceuticals (NASDAQ:TNXP)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Tonix Pharmaceuticals (NASDAQ:TNXP)
Storico
Da Set 2023 a Set 2024